Related Experiment Video
Updated: Jan 4, 2026
06:35
Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
Published on: April 27, 2016
18.5K
Role of endothelial dysfunction in heart failure
Cinzia Zuchi1, Isabella Tritto1, Erberto Carluccio1
1Cardiology and Cardiovascular Pathophysiology, Azienda Ospedaliero-Universitaria "S. Maria della Misericordia", Perugia, Italy.
Heart Failure Reviews
|November 6, 2019
Summary
Coronary artery disease contributes to heart failure, with endothelial dysfunction playing a key role. Targeting the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway may offer new therapies for heart failure.
Area of Science:
- Cardiovascular Medicine
- Pathophysiology
- Molecular Cardiology
Background:
- Coronary artery disease is a primary cause of heart failure.
- The contribution of coronary microvascular disease and endothelial dysfunction to heart failure pathophysiology is underestimated.
- Oxidative stress-induced endothelial dysfunction is a significant factor in heart failure development.
Purpose of the Study:
- To review the role of endothelial dysfunction and the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway in heart failure.
- To explore the impact of NO-cGMP pathway alterations on myocardial homeostasis and cardiac function.
- To discuss potential therapeutic strategies targeting the NO-cGMP pathway in heart failure patients.
Main Methods:
- Literature review of studies investigating endothelial function and the NO-cGMP pathway in heart failure.
- Analysis of the pathophysiology linking endothelial dysfunction, ischemia/reperfusion injury, and cardiac remodeling.
- Synthesis of current understanding of NO-cGMP pathway involvement in heart failure with reduced and preserved ejection fraction.
Main Results:
- Endothelial dysfunction contributes to systolic and diastolic dysfunction through impaired vasodilation and ischemia/reperfusion.
- Alterations in the NO-cGMP pathway directly impact myocardial homeostasis.
- Endothelial dysfunction is linked to poorer prognosis and increased cardiovascular events in heart failure patients.
Conclusions:
- The NO-cGMP pathway is critically involved in heart failure pathophysiology.
- While clinical data are still developing, the NO-cGMP pathway presents a promising therapeutic target for heart failure.
- Further research is warranted to elucidate the full therapeutic potential of targeting the NO-cGMP pathway.
Related Concept Videos
01:17Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
01:29Heart Failure II: Pathophysiology
638
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
638
01:27Heart Failure I: Introduction
639
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
639
01:26Imbalances in Cardiac Output
2.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
2.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
863
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
863
01:26Heart Failure III: Clinical Manifestations
415
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
415